This company listing is no longer active
European Biotech Acquisition Past Earnings Performance
Past criteria checks 1/6
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Capital Markets Industry Growth | 15.2% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How European Biotech Acquisition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | 1 | 2 | 0 |
| 30 Jun 22 | 0 | 2 | 1 | 0 |
| 31 Mar 22 | 0 | 3 | 1 | 0 |
Quality Earnings: 7DQ0 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if 7DQ0's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 7DQ0's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 7DQ0's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if 7DQ0's earnings growth over the past year exceeded the Capital Markets industry average.
Return on Equity
High ROE: 7DQ0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.